The Long QT syndrome is associated with potentially life-threatening cardiac arrhythmias as ventricular tachycardia (Torsade de pointes) as well as ventricular fibrillation, and might lead to syncope as well as sudden cardiac death (1). Good results have been achieved by treating patient at risk with beta blockers and implantable cardiac defibrillator (ICD). It is therefore important to diagnose the condition as early as possible as the disease is treatable (2). Prolonged QT duration might also be induced by the intake of numerous pharmaceutical substances, as well as with electrolyte disturbances, which also increases the risk of life-threatening cardiac arrhythmias. Furthermore, congenital LQTS can arise from mutations in one of at least 13 different genes. Many of these genes encode proteins which are constituents of ion channels. The genetically defined long QT syndrome has autosomal dominant (Romano Ward Syndrome) or autosomal recessive (Jervell and Lange-Nielsen Syndrome) inheritance. In this study we are using the hospital ECG database obtained with the GE Marquette 12SL ECG Analysis Program® at Telemark Hospital Skien recorded between March 2004 and April 2014. This database stores approximately 200 000 ECG recordings from 60 000 unique patients. By using the search algorithm in the MUSE ECG database, 2398 recordings have been be identified from 1603 patients where the corrected QT time is longer than 500 ms, and QRS is less than 120 ms. ECG recordings with QT intervals longer than 500 ms represents less than 1% of the population (5). Individuals having these recordings are selected for extensive clinical follow up. The patients will be offered the opportunity to have genetic analysis performed in order to distinguish between inherited or acquired long QT syndrome. The appropriate treatment will be initiated according to guidelines for patients with inherited QT syndrome. For patients with aquired long QT syndrome substitution of unfavourable pharmacotherapy or correction of electrolytes shall be performed in order to reduce their risk of cardiac arrhythmias. A T wave morphology score gives independent prognostic information useful for risk stratification. The purpose of this substudy is to examine if the T wave morphology score applied on the 1531 patients ECGs with QTc \>500 ms, has independent prognostic value in this cohort.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
survival
Timeframe: 2004-2014